Scholar Rock Welcomes Lisa Wyman as Chief Technical Officer
Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company dedicated to advancing innovative treatments for serious diseases, announced the appointment of Lisa Wyman as the new Chief Technical and Quality Officer (CTQO). This strategic addition is part of the company's initiative to evolve into a fully integrated biopharmaceutical entity, gearing up for its anticipated drug approval and market launch.
Lisa Wyman's Impressive Background
With over 20 years of expertise in technical operations and quality assurance, Ms. Wyman's extensive leadership experience is poised to be a valuable asset to Scholar Rock. Previously, she held key roles including Chief Technical Operations Officer at Generate:Biomedicines and Senior Vice President at Acceleron Pharma, where she significantly contributed to the transformation of company structures and operational strategies.
Transitioning Leadership Roles
Amid this transition, Scholar Rock is also undergoing structural changes within its executive team. The position of Chief Operating Officer (COO) has been phased out, and a search for a new Chief Financial Officer (CFO) is underway. Ted Myles, the outgoing COO and CFO, will assist the company during this transitional phase as a Senior Advisor for six months.
Strategic Vision for Growth
Dr. Jay Backstrom, the President and CEO of Scholar Rock, expressed his enthusiasm about Lisa Wyman’s appointment, highlighting her critical role in fortifying the company’s capability to bring its lead product, apitegromab, to patients. The company's ambition is to shift from its research-rooted legacy to successfully launching its first commercial product.
Achievements at Previous Companies
During her tenure at Generate:Biomedicines, Ms. Wyman successfully built a global technical operations organization aimed at supporting an array of therapeutic developments. Her leadership in Chemistry, Manufacturing, and Controls (CMC) has been pivotal in navigating complex technical challenges.
Scholar Rock’s Commitment to Innovation
Scholar Rock stands out in the biopharmaceutical landscape as a trailblazer in the biology of the transforming growth factor beta (TGF?) superfamily. The company is committed to discovering and delivering novel therapies for diseases that have high unmet needs.
Building a Promising Pipeline
At Scholar Rock, innovation is at the heart of its initiatives. Over the last decade, the company has diligently developed a pipeline designed to set new standards in treating conditions like neuromuscular diseases and cardiometabolic disorders. The focus is on harnessing targeted therapies that truly meet patient needs.
Future Directions for Scholar Rock
As Ms. Wyman joins the ranks of the Executive Team, there is great anticipation surrounding her impact on advancing the company’s goals. Her rich background in leading successful technical operations complements Scholar Rock's vision to create breakthrough therapies.
Educational Accomplishments
Ms. Wyman holds a biology degree from Ithaca College and a master's degree in engineering management from Tufts University, which equipped her with the knowledge and skills essential for driving technical excellence.
About Scholar Rock
Scholar Rock is dedicated to transforming patient care through innovative biopharmaceutical solutions, aiming to bring forth life-enhancing therapies. The organization is on a mission to address significant challenges faced by patients with serious diseases.
Frequently Asked Questions
Who is Lisa Wyman?
Lisa Wyman is the newly appointed Chief Technical and Quality Officer at Scholar Rock, bringing over 20 years of expertise in the biopharmaceutical industry.
What is Scholar Rock’s primary focus?
Scholar Rock primarily focuses on advancing treatments for serious diseases, particularly spinal muscular atrophy and cardiometabolic disorders, utilizing protein growth factors.
What changes are happening at Scholar Rock?
The company is undergoing leadership transitions, including the appointment of a new CTQO and the elimination of the COO position.
What is apitegromab?
Apitegromab is Scholar Rock’s lead product, with expectations for approval and market launch aimed at benefiting patients in need of treatment.
How is Scholar Rock structured?
Scholar Rock is structured to support a fully integrated biopharmaceutical model, driving both technical operations and quality assurance to enhance its developmental capabilities.
